Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

New CEO brings commercial nous to NetScientific

This article was originally published in Clinica

  • News

Executive Summary

NetScientific, the UK group which invests in biomedical and healthcare companies, has appointed François Martelet as CEO and board director. Dr Martelet, who will join the group on 8 June, was previously senior advisor to the CEO and interim senior vice president at biotech company Stallergenes. His 20-plus years’ of commercial experience in the biopharma industry will come in useful as a number of NetScientific’s portfolio companies start entering the commercialization phase. NetScientific has invested in several IVD companies, such as liquid biopsy technology developer Vortex Biosciences, liver disease diagnosis specialist Glycotest and ProAxsis, which is developing point of care tests for chronic conditions.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

UK MHRA’s Strategic Approach To AI Will Be ‘Proportionate’ And Fit Well Internationally

Attorney: Proposed Data Privacy Law Would Ultimately Reduce Regulatory Burden

Senseonics Wins Marketing Authorization For Novel Insulin Delivery System

Liquid Biopsy Company Karius Raised $100M To Expand Its Test For Detecting Over 1,000 Pathogens

See All
UsernamePublicRestriction

Register

MT102589

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By